Skip Navigation

European Heart Journal 2002 23(10):761-764; doi:10.1053/euhj.2001.3124
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kluft, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kluft, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

Is C-reactive protein an additional, surrogate end-point for statin treatment?

C. Kluft

Gaubius Laboratory, TNO-PG, Leiden, The Netherlands

References

  1. Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short- term effects of atorvastatin on C-reactive protein. Eur Heart J. 2002;23:794–799[Abstract/Free Full Text]
  2. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet. 1999;353:118–119[CrossRef][ISI][Medline]
  3. Tsunekawa T, Hayashi T, Kano H. Cerivastatin, a hydroxymethylglutaryl coenzyme. A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001;104:376–379[Abstract/Free Full Text]
  4. Kluft C, de Maat MPH, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Statins and C-reactive protein. Lancet. 1999;353:1274[ISI][Medline]
  5. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with Cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191–1193[Abstract/Free Full Text]
  6. Mohrschladt MF, de Maat MPM, Westendorp RGJ, Smelt AHM. C-reactive protein in patients with familial hypercholesterolemia: no effect of Simvastatin therapy. Atherosclerosis. 2001;157:491–494[CrossRef][ISI][Medline]
  7. Joukhadar C, Klein N, Prinz M. Similar effects of Atorvastatin, Simvastatin and Pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost. 2001;85:47–51[ISI][Medline]
  8. Ridker PM. High-sensitivity C-reactive protein. Potential adjunct for global assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813–1818[Abstract/Free Full Text]
  9. Ridker PM, Rifai N, Clearfield M. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–1965[Abstract/Free Full Text]
  10. Munford RS. Statins and the acute-phase response. N Engl J Med. 2001;344:2016–2018[Free Full Text]
  11. Spector TD, Hart DJ, Nandra D. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum. 1997;40:723–727[ISI][Medline]
  12. vandeRee MA, Huisman MV, Princen HMG, Meinders AE, Kluft C. Dose dependent effects of atorvastatin on C-reactive protein in type 2 diabetes mellitus. Atherosclerosis. 2001;2:79
  13. Pepys MB. The acute phase response and C-reactive protein. Weatherall DJ, Ledingham JGG, Warrell DA. Oxford Textbook of Medicine. Oxford: Oxford University Press; 1996. p. 1527–1533
  14. Azar RR, Rinfret S, Theroux P. A randomised placebo-controlled trial to assess the efficacy of anti-inflammatory therapy with methylprednisolone in unstable angina (MUNA trial). Eur Heart J. 2000;21:2026–2032[Abstract/Free Full Text]
  15. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitivity C-reactive protein levels. Circulation. 2001;103:1933–1935[Abstract/Free Full Text]
  16. Solheim S, Seljeflot I, Arnesen H, Eritsland J, Eikvar L. Reduced levels of TNF{alpha} in hypercholesterolemic individuals after treatment with Pravastatin for 8 weeks. Atherosclerosis. 2001;157:411–415[CrossRef][ISI][Medline]
  17. Deskur-Smielecka E, Wykretowicz A, Kempa M, Furmaniuk J, Wysocki H. The influence of short-term treatment with Simvastatin on the inflammatory profile of patients with hypercholesterolemia. Coron Artery Dis. 2001;12:143–148[CrossRef][Medline]
  18. Musial J, Undas A, Gajewski P, Janowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001;77:247–253[CrossRef][ISI][Medline]
  19. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Implications for plaque stabilization. Circulation. 2001;103:926–933[Abstract/Free Full Text]
  20. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47:648–657[Abstract/Free Full Text]
  21. Stefanadis C, Diamantopoulos L, Dernellis J. Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J Mol Cell Cardiol. 2000;32:43–52[CrossRef][ISI][Medline]
  22. Pepys MB, Hirschfield GM. C-reactive protein and atherothrombosis. Ital Heart J. 2001;2:196–199[Medline]
  23. Liuzzo G, Angiolillo DJ, Buffon A. Enhanced inflammatory reponse to coronary angioplasty in patients with severe angina. Circulation. 1998;98:2370–2376[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
C. Kluft
Identifying patients at risk of coronary vascular disease: the potential role of inflammatory markers
Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C21 - C27.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. Kluft and M. P.M. de Maat
Genetics of C-Reactive Protein: New Possibilities and Complications
Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 1956 - 1959.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
C. Kluft, R. Kleemann, and M.P.M. de Maat
How best to counteract the enemies? By controlling inflammation in the coronary circulation
Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G53 - G65.
[Abstract] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kluft, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kluft, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?